Mass Torts

July 20, 2026

Bard PowerPort Lawsuit

Bard PowerPort lawsuits allege that defects in implanted port catheters can cause fractures, migration, blood clots, infections, embolisms, and other serious complications. Thousands of product liability lawsuits are now pending against Bard and its parent company, Becton Dickinson, in a federal multidistrict litigation in Arizona.

The first bellwether trial ended with a partial defense verdict and a deadlocked jury on the central design defect claim. Additional trials are scheduled for 2026. Our lawyers remain bullish on well-documented fracture, migration, and embolization cases. Infection-only claims may face harder causation arguments and could receive lower settlement offers if Bard eventually proposes a global resolution.

This page provides the latest Bard PowerPort lawsuit updates, projected settlement amounts, and information about who may qualify to file a claim. No global settlement has been announced, and all payout estimates remain speculative.

July 18, 2026

Spinal Cord Stimulator Lawsuit

by Ronald V. Miller, Jr.

A spinal cord stimulator is an implantable medical device used to manage chronic pain, most often involving the back or spine. These systems are marketed as a way to reduce pain by interrupting nerve signals before they reach the brain. But for a growing number of patients, the device fails to help. It introduces new and sometimes permanent problems, including electrical shocks, burning pain, infections, lead migration, hardware failure, and repeat surgeries to reposition or remove equipment that was supposed to improve quality of life.

This page explains spinal cord stimulator lawsuits and why they are being filed nationwide. It focuses on what patients are alleging, how these devices have failed in real-world use, and why many of these cases go beyond ordinary medical malpractice claims. The most serious lawsuits do not center on a single surgical mistake. They examine how modern spinal cord stimulators were designed, tested, and approved, and whether patients were ever adequately warned about the risks that now recur repeatedly in medical records and FDA reports.

Many people arrive here with a practical question in mind: what do spinal cord stimulator settlement amounts look like, and how does compensation get calculated when a device causes lasting harm? That question cannot be answered in isolation. Settlement amounts and payouts are driven by the full medical timeline, including the costs of repeat surgeries, explantation, and permanent loss of function, as well as the downstream consequences when a pain-management device leaves someone worse off than before it was implanted.

July 15, 2026

Camp Lejeune Lawsuit News and Updates

by Ronald V. Miller, Jr.

This page provides updates on Camp Lejeune lawsuits. Our lawyers are still working to give the latest update on the litigation, even though we are no longer taking new cases. Why? Because there is little information out there, and we are staying with victims, including those we do not represent, until the end.

We have also recently reopened the comments below to answer any questions you may have or simply give you a chance to share your thoughts.

Latest Camp Lejeune Lawsuit Updates for 2026

July 14, 2026

Tylenol Autism Lawsuit

by Ronald V. Miller, Jr.

Tylenol autism lawsuits are being filed nationwide with a new Tylenol Autism class action lawsuit – technically an MDL, as we explain below – now certified in federal court.

Another Path For Victims – Baby Food

There may be another path to compensation for some victims. Plaintiffs’ Tylenol lawyers are exploring options in state court (and looking at potential baby food lawsuits for children with autism.. Those lawsuits are gaining new currency after the Tylenol cases faltered in the MDL.

July 10, 2026

Suboxone Tooth Decay Lawsuit Update

by Ronald V. Miller, Jr.

This page explains the Suboxone tooth decay lawsuits, the dental injuries linked to Suboxone film, and where the federal MDL stands in 2026.

The core claim in the Suboxone litigation is straightforward: plaintiffs allege that Indivior and related defendants knew, or should have known, that Suboxone film could cause severe dental damage, including tooth decay, enamel erosion, broken teeth, tooth loss, and expensive dental reconstruction. Plaintiffs contend the companies failed to warn patients and prescribing doctors until the FDA forced a dental warning in 2022.

Our firm is not accepting new Suboxone cases in 2026. This page is provided for litigation updates and general information for victims and their families

July 9, 2026

Depo Provera Lawsuit Settlements

by Ronald V. Miller, Jr.

This page is for victims considering filing a Depo-Provera lawsuit. Our lawyers provide the latest updates on these claims, explain the litigation process, and predict Depo Provera settlement amounts.

A new scientific study has provided stunning evidence that using Depo-Provera can cause brain tumors. Women who used Depo-Provera and subsequently developed a meningioma brain tumor can file a Depo-Provera lawsuit seeking financial compensation. This new evidence is leading to a wave of Depo-Provera lawsuits nationwide.

Our attorneys are taking these cases in all 50 states. If you think you have a Depo Provera lawsuit, call us today at 800-553-8082 or contact us online.

July 9, 2026

Vaginal Mesh Lawsuit

by Ronald V. Miller, Jr.

This page is for women considering filing a vaginal mesh lawsuit in 2026.

Vaginal mesh litigation has become one of the most significant medical device mass torts in American history. The first wave involved tens of thousands of lawsuits against manufacturers of transvaginal mesh, pelvic mesh, and mid-urethral sling products. Many of those cases have settled. But the litigation is not over. Women are still filing new vaginal mesh lawsuits in 2026, especially when they have recent revision surgery, mesh erosion, chronic pelvic pain, painful intercourse, urinary problems, bowel or bladder complications, or clear medical records tying their injuries to the mesh implant.

This page explains where vaginal mesh lawsuits stand now, who may still qualify, how new standalone cases differ from the old federal MDL system, and what settlement amounts may look like for women with strong, well-documented claims.

July 9, 2026

Hair Relaxer Lawsuit

by Ronald V. Miller, Jr.

Our lawyers are actively reviewing hair relaxer cancer lawsuits across all 50 states. These claims involve women who used chemical hair relaxers or hair straighteners and later developed uterine cancer, endometrial cancer, ovarian cancer, uterine fibroids, or complications that led to a hysterectomy.

This page explains the latest developments in the federal hair relaxer MDL, how the litigation is unfolding, which injuries are being reviewed, and how our lawyers are considering potential settlement amounts. The strongest claims generally involve long-term use of chemical hair relaxers followed by a diagnosis of uterine cancer, endometrial cancer, ovarian cancer, or severe fibroid-related injuries.

Our hair relaxer lawsuit lawyers are actively representing victims nationwide. Call our attorneys today at 800-553-8082 or get a free online consultation.

July 9, 2026

Monsanto Roundup Lawsuit Update

by Ronald V. Miller, Jr.

In this post, our Roundup lawyers will give you:

An update on where things stand in the new $7.5 billion Roundup class action lawsuit settlement in June 2026
The likely direction the Roundup litigation will take moving forward, and

July 6, 2026

Dupixent Lawsuit for T-Cell Lymphoma

by Ronald V. Miller, Jr.

Dupixent lawsuits are now moving forward in federal court for patients who allege the drug caused, accelerated, or unmasked cutaneous T-cell lymphoma and related T-cell lymphomas. On June 4, 2026, the Judicial Panel on Multidistrict Litigation centralized the federal Dupixent cases in MDL No. 3180, In re: Dupixent (Dupilumab) Products Liability Litigation, in the District of New Jersey before Judge Zahid N. Quraishi.

Dupixent, also known as dupilumab, is a biologic medication used to treat atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, COPD, bullous pemphigoid, allergic fungal rhinosinusitis, and other inflammatory conditions. For many patients, Dupixent has provided real relief where other treatments failed. But for some patients, the story has been very different.

The lawsuits allege that Regeneron and Sanofi failed to warn doctors and patients that cutaneous T-cell lymphoma, often called CTCL, can mimic eczema and that Dupixent may mask, accelerate, or delay diagnosis of an underlying lymphoma. Plaintiffs argue that patients with adult-onset, atypical, or treatment-resistant dermatitis should have been warned to rule out lymphoma before starting Dupixent and to stop and investigate if symptoms worsened or changed during treatment.